Boston Scientific Corporation's Stock Analysis

Boston Scientific Initiates $2 Billion Share Repurchase Program

Boston Scientific Corporation has announced an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank for $2 billion of its common stock, part of a larger $5 billion share repurchase authorization. The ASR is expected to provide the company with approximately 30.4 million shares based on the closing price of $52.68 as of May 15, 2026. The final number of shares repurchased will be determined by the average stock price during the ASR period, with completion anticipated by June 30, 2026. After the ASR, Boston Scientific will have $3 billion remaining under its share repurchase program.

The expected impact on adjusted earnings per share for the full year 2026 from this ASR is an increase of $0.02, which is an addition to the company's previously issued guidance. This initiative reflects Boston Scientific's ongoing strategy to enhance shareholder value through share repurchases.

May 18, 2026 07:17:15

Boston Scientific Invests $1.5 Billion in MiRus LLC Partnership

Boston Scientific Corporation has entered into an investment agreement with MiRus LLC, acquiring a 33.75% equity stake for $1.5 billion. MiRus is focused on developing innovative biomaterials and procedural solutions for cardiovascular and orthopedic diseases, including the Siegel transcatheter aortic valve replacement (TAVR) system, which has received FDA approval for clinical trials aimed at gaining premarket approval.

Additionally, the agreement includes an exclusive option for Boston Scientific to acquire MiRus's TAVR business for an additional $3 billion, contingent upon meeting specific clinical and regulatory milestones. If the option is exercised, MiRus will also be entitled to receive further payments based on net sales of the TAVR system. This investment is anticipated to have an immaterial impact on Boston Scientific's adjusted earnings per share for 2026.

May 18, 2026 07:15:03

Boston Scientific Stockholders Approve Key Corporate Amendments

On April 30, 2026, Boston Scientific's stockholders approved several amendments to the Company's Third Restated Certificate of Incorporation during the Annual Meeting. These amendments include the elimination of supermajority voting provisions and the exculpation of certain officers as allowed by Delaware law. The amendments took effect on May 5, 2026, following the filing of the Fourth Restated Certificate of Incorporation.

During the Annual Meeting, all 10 director nominees were elected for a one-year term, and stockholders approved the compensation of Named Executive Officers, the appointment of Ernst & Young LLP as the independent auditor for the 2026 fiscal year, and an increase in shares for the Employee Stock Purchase Plan. However, stockholders did not approve proposals allowing shareholders to call special meetings or the related amendments to the bylaws.

May 05, 2026 16:47:18

Boston Scientific Stockholder Meeting Results and Corporate Amendments

On April 30, 2026, Boston Scientific's stockholders approved several amendments to the Company’s Third Restated Certificate of Incorporation. These changes included the elimination of supermajority voting provisions, the clarification of certain inoperative provisions, and the exculpation of specific officers as allowed by Delaware law. The amendments took effect following the filing of the Fourth Restated Certificate of Incorporation on May 5, 2026.

During the virtual Annual Meeting, stockholders elected all 10 director nominees for a one-year term and approved the advisory compensation for Named Executive Officers. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year, and the Employee Stock Purchase Plan was amended to increase the number of shares available. However, stockholders did not approve proposals allowing stockholders owning at least 25% of common stock to call special meetings.

May 05, 2026 16:47:18

Boston Scientific Reports Q1 2026 Financial Results and Growth

Boston Scientific Corporation reported net sales of $5.203 billion for the first quarter of 2026, marking an 11.6% increase compared to the same period last year. The company achieved a GAAP net income of $1.341 billion, or $0.90 per share, up from $674 million or $0.45 per share in the previous year. Adjusted earnings per share (EPS) for the quarter were $0.80, slightly above the guidance range. Growth was driven by strong performance in the MedSurg and Cardiovascular segments, with significant sales increases across all major regions, particularly in Asia-Pacific and Latin America.

In addition to financial results, Boston Scientific announced several clinical trial successes and received regulatory approvals for new products. The company also completed the acquisition of Valencia Technologies Corporation, expanding its portfolio in urinary incontinence treatment. Looking ahead, Boston Scientific estimates net sales growth for the full year 2026 to be approximately 7.0% to 8.5% on a reported basis, with adjusted EPS projected between $3.34 and $3.41. The second quarter guidance suggests net sales growth of 5.5% to 7.5% and adjusted EPS of $0.82 to $0.84.

Apr 22, 2026 06:34:16

Boston Scientific Announces Positive Clinical Trial Results for Devices

Boston Scientific Corporation reported positive results from two clinical trials on March 28, 2026. The HI-PEITHO trial demonstrated that the EKOS™ Endovascular System significantly reduced clinical events in patients with intermediate-risk pulmonary embolism compared to standard anticoagulation treatment. The trial showed a 61% reduction in primary endpoint events, with no increased risk of major bleeding and shorter hospital stays for patients treated with the EKOS system.

Additionally, the CHAMPION-AF trial confirmed the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction in patients with non-valvular atrial fibrillation. The device showed a statistically significant reduction in bleeding risk compared to non-vitamin K antagonist oral anticoagulants, while maintaining comparable efficacy in preventing strokes. These findings may influence clinical guidelines and expand the use of the WATCHMAN device in treating patients with atrial fibrillation.

Mar 30, 2026 06:14:18

Boston Scientific Secures $11 Billion in New Credit Agreements

Boston Scientific Corporation has entered into three significant credit agreements totaling $11 billion. This includes a $3 billion revolving credit agreement maturing in 2031, a $2 billion 364-day revolving credit agreement, and a $6 billion term loan credit agreement. The term loan may be utilized to fund the acquisition of Penumbra, Inc. The agreements stipulate various interest rates based on the company’s credit rating and include provisions for maintaining a maximum leverage ratio.

Additionally, the company has terminated a previous revolving credit agreement from May 2021 in conjunction with the new agreements. The new credit facilities are structured to support the company’s financial flexibility and strategic acquisitions, with specific terms regarding borrowing, repayment, and financial covenants that may impact the company's overall financial health.

Feb 26, 2026 17:11:42

Boston Scientific Secures $11 Billion in New Credit Facilities

Boston Scientific Corporation has entered into three significant credit agreements totaling $11 billion, including a $3 billion revolving credit agreement and a $6 billion term loan credit agreement. The revolving credit agreements, which mature in 2026 and 2031, allow the company to borrow funds for operational flexibility, while the term loan is intended to finance the acquisition of Penumbra, Inc. The agreements include interest rates tied to the company's credit rating and various financial covenants, including a maximum leverage ratio requirement.

In conjunction with the new credit agreements, Boston Scientific has terminated a prior revolving credit agreement from 2021. The new arrangements are designed to enhance the company's liquidity and support its strategic initiatives. The terms of the agreements also require compliance with certain financial metrics, which could impact the company's financial health and borrowing capacity in the future.

Feb 26, 2026 17:11:42

Boston Scientific Expands Board and Increases Stock Buyback Program

Boston Scientific Corporation has appointed Catherine R. Smith and Christophe P. Weber to its Board of Directors, effective February 18, 2026. Smith will serve on the Audit Committee and Nominating and Governance Committee, while Weber will join the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee. Both directors will receive prorated compensation under the company's non-employee director compensation program, which includes a cash retainer and an equity award.

Additionally, the Board has approved an increase in the stock repurchase program, raising the total authorization to $5.0 billion. This decision follows the retirements of directors John Sununu and Yoshiaki Fujimori, who will not seek re-election at the upcoming 2026 annual meeting. The company's strategic focus remains on innovation and improving patient care, supported by the newly appointed directors' extensive experience in their respective fields.

Feb 23, 2026 16:33:54

Boston Scientific Director Yoshiaki Fujimori to Depart Board

Yoshiaki Fujimori has announced he will not seek re-election at Boston Scientific's 2026 Annual Meeting. He has been a board member since July 2016 and currently chairs the Risk, Science and Technology Committee. Fujimori will remain in his roles until the 2026 Annual Meeting.

His decision to step down is not due to any disagreement with the company. The Board and Nominating and Governance Committee will continue to assess the board's composition and consider potential new directors following Fujimori's departure.

Feb 05, 2026 16:21:28